Rapid, Reversible Modulation of Blood–Brain BarrierP-Glycoprotein Transport Activity by Vascular Endothelial Growth Factor
Authors:
- Brian T. HawkinsBHBrian T. Hawkins
- Destiny B. SykesDSDestiny B. Sykes
- David S. MillerDMDavid S. Miller
Open Access
- 27 January 2010
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 30 (4) , 1417-1425
Abstract
Increased brain expression of vascular endothelial growth factor (VEGF) is associated with neurological disease, brain injury, and blood–brain barrier (BBB) dysfunction. However, the specific effect of VEGF on the efflux transporter P-glycoprotein, a critical component of the BBB, is not known. Using isolated rat brain capillaries andin siturat brain perfusion, we determined the effect of VEGF exposure on P-glycoprotein activityin vitroandin vivo. In isolated capillaries, VEGF acutely and reversibly decreased P-glycoprotein transport activity without decreasing transporter protein expression or opening tight junctions. This effect was blocked by inhibitors of the VEGF receptor flk-1 and Src kinase, but not by inhibitors of phosphatidylinositol-3-kinase or protein kinase C. VEGF also increased Tyr-14 phosphorylation of caveolin-1, and this was blocked by the Src inhibitor PP2. Pharmacological activation of Src kinase activity mimicked the effects of VEGF on P-glycoprotein activity and Tyr-14 phosphorylation of caveolin-1.In vivo, intracerebroventricular injection of VEGF increased brain distribution of P-glycoprotein substrates morphine and verapamil, but not the tight junction marker, sucrose; this effect was blocked by PP2. These findings indicate that VEGF decreases P-glycoprotein activity via activation of flk-1 and Src, and suggest Src-mediated phosphorylation of caveolin-1 may play a role in downregulation of P-glycoprotein activity. These findings also imply that P-glycoprotein activity is acutely diminished in pathological conditions associated with increased brain VEGF expression and that BBB VEGF/Src signaling could be targeted to acutely modulate P-glycoprotein activity and thus improve brain drug delivery.Keywords
This publication has 50 references indexed in Scilit:
- Evidence of angiogenic vessels in Alzheimer’s diseaseJournal of Neural Transmission, 2009
- Dosing and safety of cyclosporine in patients with severe brain injuryJournal of Neurosurgery, 2008
- Peripheral nerve damage associated with administration of taxanes in patients with cancerCritical Reviews in Oncology/Hematology, 2008
- Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System PharmacotherapyPharmacological Reviews, 2008
- A Genomic Comparison of in vivo and in vitro Brain Microvascular Endothelial CellsJournal of Cerebral Blood Flow & Metabolism, 2007
- Flt‐1, but not Flk‐1 mediates hyperpermeability through activation of the PI3‐K/Akt pathwayJournal of Cellular Physiology, 2007
- Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-α and LipopolysaccharideMolecular Pharmacology, 2006
- VEGF signalling: integration and multi-tasking in endothelial cell biologyBiochemical Society Transactions, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementiaNeurobiology of Aging, 2002